Samuel Goldlust

4.0k total citations
40 papers, 564 citations indexed

About

Samuel Goldlust is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Samuel Goldlust has authored 40 papers receiving a total of 564 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Genetics, 15 papers in Pulmonary and Respiratory Medicine and 13 papers in Oncology. Recurrent topics in Samuel Goldlust's work include Glioma Diagnosis and Treatment (35 papers), Brain Metastases and Treatment (12 papers) and Cancer Genomics and Diagnostics (8 papers). Samuel Goldlust is often cited by papers focused on Glioma Diagnosis and Treatment (35 papers), Brain Metastases and Treatment (12 papers) and Cancer Genomics and Diagnostics (8 papers). Samuel Goldlust collaborates with scholars based in United States, Japan and Germany. Samuel Goldlust's co-authors include Herbert B. Newton, Dennis K. Pearl, Lisa M. DeAngelis, Andrei I. Holodny, Mustafa Khasraw, Narendra Nathoo, Michael A. Vogelbaum, Rekha Chaudhary, Stephen Marcus and Adam L. Cohen and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Samuel Goldlust

39 papers receiving 537 citations

Peers

Samuel Goldlust

GENET

PRM

ONCOL

PMH

Maria Piribauer Austria

Edvina Galiè Italy

Stanisław Nowak Poland

Joon‐Khim Loh Taiwan

N. Roosen Germany

Zhipeng Wen China

Min Cheol Lee South Korea

A. Pozzi Italy

Faranak Azarbayjani Sweden

Joon Ho Song South Korea

Maria Piribauer Austria

Samuel Goldlust

341 ×1.1

GENET

113 ×0.8

PRM

169 ×1.2

105 ×0.9

ONCOL

73 ×0.7

PMH

Citations per year, relative to Samuel Goldlust Samuel Goldlust (= 1×) peers Maria Piribauer

Countries citing papers authored by Samuel Goldlust

Since Specialization

Citations

This map shows the geographic impact of Samuel Goldlust's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel Goldlust with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel Goldlust more than expected).

Fields of papers citing papers by Samuel Goldlust

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel Goldlust. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel Goldlust. The network helps show where Samuel Goldlust may publish in the future.

Co-authorship network of co-authors of Samuel Goldlust

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel Goldlust. A scholar is included among the top collaborators of Samuel Goldlust based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel Goldlust. Samuel Goldlust is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goldlust, Samuel, Burt Nabors, Sigmund Hsu, et al.. (2024). Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma. Neuro-Oncology Advances. 6(1). vdae009–vdae009. 1 indexed citations

Khagi, Simon, Rupesh Kotecha, Na Tosha Gatson, et al.. (2024). Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma. The Oncologist. 30(2). 10 indexed citations

Goldlust, Samuel, et al.. (2024). Phase 1 study of concomitant tumor treating fields and temozolomide chemoradiation for newly diagnosed glioblastoma. Neuro-Oncology Advances. 6(1). vdae129–vdae129. 1 indexed citations

Shi, Wenyin, Lawrence Kleinberg, Suriya Jeyapalan, et al.. (2023). Abstract CT061: TRIDENT phase 3 study (EF-32): First-line Tumor Treating Fields (TTFields; 200 kHz) therapy concomitant with chemo-radiation, followed by maintenance TTFields/temozolomide in newly diagnosed glioblastoma. Cancer Research. 83(8_Supplement). CT061–CT061. 1 indexed citations

Goldlust, Samuel, Jong Hee Chang, Yoshitaka Narita, et al.. (2023). Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM).. Journal of Clinical Oncology. 41(16_suppl). 2022–2022. 1 indexed citations

Zhu, Jay‐Jiguang, Samuel Goldlust, Lawrence Kleinberg, et al.. (2022). Tumor Treating Fields (TTFields) therapy vs physicians’ choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19). Discover Oncology. 13(1). 105–105. 9 indexed citations

Reardon, David A., Yoshitaka Narita, Yoshiki Arakawa, et al.. (2022). DSP-0390, an oral emopamil binding protein (EBP) inhibitor, in patients with recurrent high-grade glioma: A first-in-human, phase 1 study.. Journal of Clinical Oncology. 40(16_suppl). TPS2077–TPS2077. 2 indexed citations

Wen, Patrick Y., John de Groot, James Battiste, et al.. (2022). 280O Pharmacokinetics and pharmacodynamics of paxalisib in newly diagnosed glioblastoma patients with unmethylated MGMT promoter status: Final phase II study results. Annals of Oncology. 33. S667–S667. 3 indexed citations

Goldlust, Samuel, et al.. (2021). Tetrodotoxin for Chemotherapy-Induced Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Finding Trial. Toxins. 13(4). 235–235. 24 indexed citations

10.

Wen, Patrick Y., John de Groot, James Battiste, et al.. (2021). Abstract LB125: Pharmacokinetics of paxalisib in phase 2 clinical study in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status. Cancer Research. 81(13_Supplement). LB125–LB125. 3 indexed citations

11.

Huang, Jiayi, Rekha Chaudhary, Adam L. Cohen, et al.. (2019). A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. Journal of Neuro-Oncology. 142(3). 537–544. 82 indexed citations

12.

Zhu, Jay‐Jiguang, Andrew A. Kanner, Susan C. Pannullo, et al.. (2017). Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. Journal of Neuro-Oncology. 135(3). 545–552. 50 indexed citations

13.

Weller, Michael, Nicholas Butowski, David Tran, et al.. (2016). ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA. Neuro-Oncology. 18(suppl_6). vi17–vi18. 41 indexed citations

14.

Schaff, Lauren, Andrew B. Lassman, Samuel Goldlust, et al.. (2014). ET-53 * IPILIMUMAB FOR RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology. 16(suppl 5). v90–v90. 4 indexed citations

15.

Goldlust, Samuel, Meier Hsu, Andrew B. Lassman, Katherine S. Panageas, & Edward K. Avila. (2012). Seizure prophylaxis and melanoma brain metastases. Journal of Neuro-Oncology. 108(1). 109–114. 25 indexed citations

16.

Goldlust, Samuel, Robert Cavaliere, Herbert B. Newton, et al.. (2011). Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors. Journal of Neuro-Oncology. 107(2). 407–411. 13 indexed citations

17.

Khasraw, Mustafa, Andrei I. Holodny, Samuel Goldlust, & Lisa M. DeAngelis. (2011). Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. Annals of Oncology. 23(2). 458–463. 47 indexed citations

18.

Newton, Herbert B., et al.. (2007). Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. Journal of Neuro-Oncology. 84(3). 293–296. 31 indexed citations

19.

Newton, Herbert B., Samuel Goldlust, & Dennis K. Pearl. (2006). Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. Journal of Neuro-Oncology. 78(1). 99–102. 89 indexed citations

20.

Nathoo, Narendra, Samuel Goldlust, & Michael A. Vogelbaum. (2004). EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS: NOVEL THERAPY FOR THE TREATMENT OF HIGH-GRADE GLIOMAS. Neurosurgery. 54(6). 1480–1489. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact